The “TCR Therapy- Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in TCR Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The TCR is a disulfide-linked membrane-anchored heterodimeric protein normally consisting of the highly variable alpha (α) and beta (β) chains expressed as part of a complex with the invariant CD3 chain molecules. T cells expressing this receptor are referred to as α:β (or αβ) T cells, though a minority of T cells express an alternate receptor, formed by variable gamma (γ) and delta (δ) chains, referred as γδ T cells. Each chain is composed of two extracellular domains: Variable (V) region and a Constant (C) region, both of Immunoglobulin superfamily (IgSF) domain forming antiparallel β-sheets. The Constant region is proximal to the cell membrane, followed by a transmembrane region and a short cytoplasmic tail, while the Variable region binds to the peptide/MHC complex.
Successfully rearranged TCRs are expressed at the T cell surface and audition for selection on thymic self-pMHC ligands. The net result of thymic selection is that the post-selection repertoire is largely purged of most clonotypes. Typically, only one in a hundred thymocytes are thought to be granted access to the periphery. Assessing the relative distribution of TCR clonotypes has long been a challenge in the naive pool because of low precursor frequency. Nevertheless, identifying the factors that shape the composition of the naive repertoire is critical to understanding of protective T cell-mediated immunity because naive lymphocytes represent the precursor pool from which all immune responses arise.
Improving the function of TCR-engineered T cells is critical to overcome inhibitory factors within the tumor microenvironment and elicit tumor regression. Many efforts to enhance antigen reactivity and circumvent T cell tolerance have focused on increasing TCR signal strength and generating highly functional T cells. Immune checkpoint proteins, such as PD-1 and CTLA-4, can prevent the activation of T cells in immune system. A recent study demonstrating the benefits of this approach created CD8+ T cells expressing two additional receptors; a gp100 antigen-specific TCR and a melanoma-associated chondroitin sulfate proteoglycan specific CAR. These T cells using combined recognition pathways showed greater efficacy by by-passing the mechanisms by which tumor cells escape immune recognition. In conclusion, TCR-engineered T cells therapy, in combination with drugs targeting chemokines, cytokines, and immune checkpoint proteins, may obtain better clinical responses in future treatments.
"TCR Therapy- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TCR Therapy pipeline landscape is provided which includes the disease overview and TCR Therapy treatment guidelines. The assessment part of the report embraces, in depth TCR Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 2-4 business days.
Geography Covered
- Global coverage
TCR Therapy: Understanding
TCR Therapy: Overview
The T-cell receptor (TCR) is a molecule found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate, that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.The TCR is a disulfide-linked membrane-anchored heterodimeric protein normally consisting of the highly variable alpha (α) and beta (β) chains expressed as part of a complex with the invariant CD3 chain molecules. T cells expressing this receptor are referred to as α:β (or αβ) T cells, though a minority of T cells express an alternate receptor, formed by variable gamma (γ) and delta (δ) chains, referred as γδ T cells. Each chain is composed of two extracellular domains: Variable (V) region and a Constant (C) region, both of Immunoglobulin superfamily (IgSF) domain forming antiparallel β-sheets. The Constant region is proximal to the cell membrane, followed by a transmembrane region and a short cytoplasmic tail, while the Variable region binds to the peptide/MHC complex.
Successfully rearranged TCRs are expressed at the T cell surface and audition for selection on thymic self-pMHC ligands. The net result of thymic selection is that the post-selection repertoire is largely purged of most clonotypes. Typically, only one in a hundred thymocytes are thought to be granted access to the periphery. Assessing the relative distribution of TCR clonotypes has long been a challenge in the naive pool because of low precursor frequency. Nevertheless, identifying the factors that shape the composition of the naive repertoire is critical to understanding of protective T cell-mediated immunity because naive lymphocytes represent the precursor pool from which all immune responses arise.
Improving the function of TCR-engineered T cells is critical to overcome inhibitory factors within the tumor microenvironment and elicit tumor regression. Many efforts to enhance antigen reactivity and circumvent T cell tolerance have focused on increasing TCR signal strength and generating highly functional T cells. Immune checkpoint proteins, such as PD-1 and CTLA-4, can prevent the activation of T cells in immune system. A recent study demonstrating the benefits of this approach created CD8+ T cells expressing two additional receptors; a gp100 antigen-specific TCR and a melanoma-associated chondroitin sulfate proteoglycan specific CAR. These T cells using combined recognition pathways showed greater efficacy by by-passing the mechanisms by which tumor cells escape immune recognition. In conclusion, TCR-engineered T cells therapy, in combination with drugs targeting chemokines, cytokines, and immune checkpoint proteins, may obtain better clinical responses in future treatments.
"TCR Therapy- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TCR Therapy pipeline landscape is provided which includes the disease overview and TCR Therapy treatment guidelines. The assessment part of the report embraces, in depth TCR Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence TCR Therapy R&D. The therapies under development are focused on novel approaches to treat/improve TCR Therapy.TCR Therapy Emerging Drugs Chapters
This segment of the TCR Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.TCR Therapy Emerging Drugs
- Brenetafusp: Immunocore
- TAEST 16001: Guangdong Xiangxue Precision Medical Technology Co., Ltd
- NT-175: Neogene Therapeutics
- TSC 101: TScan Therapeutics
- SCG 162: SCG Cell Therapy
TCR Therapy: Therapeutic Assessment
This segment of the report provides insights about the different TCR Therapy drugs segregated based on following parameters that define the scope of the report, such as:Major Players in TCR Therapy
There are approx. 80+ key companies which are developing the therapies for TCR Therapy. The companies which have their TCR Therapy drug candidates in the most advanced stage, i.e. Phase III include, Immunocore.Phases
The report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
TCR Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.TCR Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TCR Therapy therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TCR Therapy drugs.TCR Therapy Report Insights
- TCR Therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
TCR Therapy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing TCR Therapy drugs?
- How many TCR Therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TCR Therapy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TCR Therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TCR Therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Immunocore
- Guangdong Xiangxue Precision Medical Technology Co., Ltd
- Neogene Therapeutics
- TScan Therapeutics
- SCG Cell Therapy
- Triumvira
- JW Therapeutics
- Immatics
- China Immunotech
- T-Cure
- 2seventy bio
Key Products
- Brenetafusp
- TAEST 16001
- NT-175
- TSC 101
- SCG 162
- TAC01 HER2
- ECT204
- TSC-100
- IMA201
- CMV TCR-T
- 820 TCR
- MAGE-A4 TCR program
This product will be delivered within 2-4 business days.
Table of Contents
IntroductionExecutive SummaryTCR Therapy - Analytical PerspectiveTCR Therapy Key CompaniesTCR Therapy Key ProductsTCR Therapy - Unmet NeedsTCR Therapy - Market Drivers and BarriersTCR Therapy - Future Perspectives and ConclusionTCR Therapy Analyst ViewsTCR Therapy Key CompaniesAppendix
TCR Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Brenetafusp: Immunocore
Mid Stage Products (Phase II)
TAEST 16001: Guangdong Xiangxue Precision Medical Technology Co., Ltd
Early Stage Products (Phase I)
NT-175: Neogene Therapeutics
Preclinical and Discovery Stage Products
SCG 162: SCG Cell Therapy
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Immunocore
- Guangdong Xiangxue Precision Medical Technology Co., Ltd
- Neogene Therapeutics
- TScan Therapeutics
- SCG Cell Therapy
- Triumvira
- JW Therapeutics
- Immatics
- China Immunotech
- T-Cure
- 2seventy bio
